P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000848644.19354.c7 |
| _version_ | 1797287256599298048 |
|---|---|
| author | V. Bücklein A. Perez G. Iacoboni K. Rejeski U. Holtick O. Penack S. Kharboutli V. Blumenberg J. Ackermann L. Frölich G. Johnson K. Patel B. Arciola C. Schmidt O. Albanyan P. Gödel E. Hoster L. Bullinger A. Mackensen F. Locke M. von Bergwelt P. Barba M. D. Jain M. Subklewe |
| author_facet | V. Bücklein A. Perez G. Iacoboni K. Rejeski U. Holtick O. Penack S. Kharboutli V. Blumenberg J. Ackermann L. Frölich G. Johnson K. Patel B. Arciola C. Schmidt O. Albanyan P. Gödel E. Hoster L. Bullinger A. Mackensen F. Locke M. von Bergwelt P. Barba M. D. Jain M. Subklewe |
| author_sort | V. Bücklein |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:30:16Z |
| format | Article |
| id | doaj.art-c1f54c7a377e4248a5b038c243dcaa82 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:30:16Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-c1f54c7a377e4248a5b038c243dcaa822024-03-02T06:40:31ZengWileyHemaSphere2572-92412022-06-0161330133110.1097/01.HS9.0000848644.19354.c7202206003-01330P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICEV. Bücklein0A. Perez1G. Iacoboni2K. Rejeski3U. Holtick4O. Penack5S. Kharboutli6V. Blumenberg7J. Ackermann8L. Frölich9G. Johnson10K. Patel11B. Arciola12C. Schmidt13O. Albanyan14P. Gödel15E. Hoster16L. Bullinger17A. Mackensen18F. Locke19M. von Bergwelt20P. Barba21M. D. Jain22M. Subklewe231 Department of Medicine III, University Hospital, University of Munich3 Blood & Marrow Transplant Program, Miami Cancer Institute, Miami5 Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Department of Medicine, Universitat Autònoma of Barcelona (UAB), Barcelona, Spain1 Department of Medicine III, University Hospital, University of Munich7 Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne8 Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin9 Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany1 Department of Medicine III, University Hospital, University of Munich1 Department of Medicine III, University Hospital, University of Munich1 Department of Medicine III, University Hospital, University of Munich10 USF Health Morsani College of Medicine, Tampa, United States of America10 USF Health Morsani College of Medicine, Tampa, United States of America10 USF Health Morsani College of Medicine, Tampa, United States of America1 Department of Medicine III, University Hospital, University of Munich4 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States of America7 Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne11 Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany8 Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin9 Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany4 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States of America1 Department of Medicine III, University Hospital, University of Munich5 Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Department of Medicine, Universitat Autònoma of Barcelona (UAB), Barcelona, Spain4 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States of America1 Department of Medicine III, University Hospital, University of Munichhttp://journals.lww.com/10.1097/01.HS9.0000848644.19354.c7 |
| spellingShingle | V. Bücklein A. Perez G. Iacoboni K. Rejeski U. Holtick O. Penack S. Kharboutli V. Blumenberg J. Ackermann L. Frölich G. Johnson K. Patel B. Arciola C. Schmidt O. Albanyan P. Gödel E. Hoster L. Bullinger A. Mackensen F. Locke M. von Bergwelt P. Barba M. D. Jain M. Subklewe P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE HemaSphere |
| title | P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE |
| title_full | P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE |
| title_fullStr | P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE |
| title_full_unstemmed | P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE |
| title_short | P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE |
| title_sort | p1447 inferior outcomes of eu vs us patients with relapsed refractory large b cell lymphoma after cd19 car t cell therapy are impacted by baseline risk factors and car product choice |
| url | http://journals.lww.com/10.1097/01.HS9.0000848644.19354.c7 |
| work_keys_str_mv | AT vbucklein p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT aperez p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT giacoboni p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT krejeski p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT uholtick p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT openack p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT skharboutli p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT vblumenberg p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT jackermann p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT lfrolich p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT gjohnson p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT kpatel p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT barciola p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT cschmidt p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT oalbanyan p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT pgodel p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT ehoster p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT lbullinger p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT amackensen p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT flocke p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT mvonbergwelt p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT pbarba p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT mdjain p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice AT msubklewe p1447inferioroutcomesofeuvsuspatientswithrelapsedrefractorylargebcelllymphomaaftercd19cartcelltherapyareimpactedbybaselineriskfactorsandcarproductchoice |